(Q38876360)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27342605%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

review article

1 reference

title

Drug Development of Therapeutic Monoclonal Antibodies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27342605%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27342605%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

author name string

Diane R Mould

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27342605%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

publication date

1 August 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27342605%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27342605%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27342605%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27342605%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

page(s)

275-293

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27342605%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s40259-016-0181-6

15 March 2020

exact match

0 references

cites work

Signaling antibodies in cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Technology insight: cytotoxic drug immunoconjugates for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Progressive multifocal leukoencephalopathy: current treatment options and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

High throughput ranking of recombinant avian scFv antibody fragments from crude lysates using the Biacore A100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Kinetic screening of antibodies from crude hybridoma samples using Biacore

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Preclinical and clinical safety of monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Preclinical safety testing of monoclonal antibodies: the significance of species relevance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Advances in surface plasmon resonance biosensor analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Experimental design for kinetic analysis of protein-protein interactions with surface plasmon resonance biosensors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Biacore surface matrix effects on the binding kinetics and affinity of an antigen/antibody complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Characterizing high-affinity antigen/antibody complexes by kinetic- and equilibrium-based methods.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Kinetic exclusion assay technology: characterization of molecular interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

A rigorous multiple independent binding site model for determining cell-based equilibrium dissociation constants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Mathematical modeling of receptor occupancy data: A valuable technology for biotherapeutic drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Pharmacokinetic/pharmacodynamic studies in drug product development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Prediction of exposure-response relationships to support first-in-human study design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Arthritis induced in rats with nonimmunogenic adjuvants as models for rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Modeling pharmacokinetics/pharmacodynamics of abatacept and disease progression in collagen-induced arthritic rats: a population approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Pharmacokinetic-pharmacodynamic disease progression model for effect of etanercept in Lewis rats with collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Quantitative dynamic models of arthritis progression in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

21 January 2018

Building a better Trap

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Angiogenesis in cancer and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Fit-for purpose use of mouse models to improve predictivity of cancer therapeutics evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Preclinical development of monoclonal antibodies: considerations for the use of non-human primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Regulating biopharmaceuticals under CDER versus CBER: an insider's perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Human regulatory T cells are selectively activated by low-dose application of the CD28 superagonist TGN1412/TAB08.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Clinical pharmacokinetics of bevacizumab in patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Pharmacokinetic aspects of biotechnology products

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

The antibody drug absorption following subcutaneous or intramuscular administration and its mathematical description by coupling physiologically based absorption process with the conventional compartment pharmacokinetic model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

A Bottom-Up Whole-Body Physiologically Based Pharmacokinetic Model to Mechanistically Predict Tissue Distribution and the Rate of Subcutaneous Absorption of Therapeutic Proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Giving monoclonal antibodies to healthy volunteers in phase 1 trials: is it safe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Clinical Development Strategies and Outcomes in First-in-Human Trials of Monoclonal Antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Management of adverse events in the treatment of patients with immunoglobulin therapy: A review of evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Clinical pharmacology of bispecific antibody constructs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Characterizing the impact of renal impairment on the clinical pharmacology of biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Pharmacokinetics of ranibizumab after intravitreal administration in patients with retinal vein occlusion or diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Contribution of renal and non-renal clearance on increased total clearance of adalimumab in glomerular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Population pharmacokinetics of belimumab following intravenous administration in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Pharmacokinetics of panitumumab in a patient with liver dysfunction: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Rational development and utilization of antibody-based therapeutic proteins in pediatrics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Challenges and considerations for development of therapeutic proteins in pediatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of monoclonal antibodies in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

General pharmacokinetic model for drugs exhibiting target-mediated drug disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Physiologically based pharmacokinetic (PBPK) modeling in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

The in silico child: using simulation to guide pediatric drug development and manage pediatric pharmacotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Outcomes following infliximab therapy for pediatric patients hospitalized with refractory colitis-predominant IBD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Alemtuzumab: a review of its use in patients with relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Population pharmacokinetics and exposure-response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Dashboard systems: Pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Population pharmacokinetics. Theory and clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Concepts and challenges in quantitative pharmacology and model-based drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Population pharmacokinetics of therapeutic monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Are international differences in the outcomes of acute coronary syndromes apparent or real? A multilevel analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Cytochrome P450 variations in different ethnic populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Population pharmacokinetics of infliximab in patients with ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Screening antibody–antigen interactions in parallel using Biacore A100

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

Pharmacokinetics and Pharmacodynamics of Peptide and Protein Therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0181-6

10.1007/S40259-016-0181-6

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27342605%20AND%20SRC:MED&resulttype=core&format=json

15 March 2020

1 reference